latest news releases from the newsroom
Case-Mate Debuts Its New Collection of Trend-Setting Cases for the iPhone 6 and iPhone 6 Plus
ATLANTA, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Case-Mate®, the industry-leading designers of fashion-forward and finely crafted cases for smartphones and tablets, unveils its latest collection of cases for the new Apple® iPhone 6 and iPhone 6 Plus. Created with a thoughtful approach to stylish materials, enhanced protection and finishing detail, Case-Mate's latest collections of iPhone 6 and iPhone 6 Plus cases are now available at
Columbus McKinnon Corporation
Columbus McKinnon to Present at the 2014 Western New York Investors Conference
AMHERST, N.Y., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Columbus McKinnon Corporation (Nasdaq:CMCO), a leading designer, manufacturer and marketer of material handling products, announced today that President and Chief Executive Officer Timothy T. Tevens and Vice President - Finance and Chief Financial Officer Gregory P. Rustowicz will present to institutional investors and analysts at the 2014 Western New York Investors Conference on Friday, September 26, 2014 in Buffalo, New York.
Corium International, Inc.
Corium Announces Appointment of Paul Goddard, Ph.D. to Board of Directors
MENLO PARK, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Paul Goddard, Ph.D. to the Company's Board of Directors.
Five Prime Therapeutics, Inc.
Five Prime Therapeutics Appoints Dr. Robert Sikorski as Vice President of Global Clinical Development
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for Five Prime's product candidates.
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 2 study to evaluate the safety and activity of fosbretabulin monotherapy in patients with locally advanced, recurrent or metastatic gastrointestinal neuroendocrine tumors, or GI-NETs, with elevated biomarkers. GI-NETs are slow-growing, often invasive tumors that produce excessive amounts of hormones and other peptides which enter the blood stream and cause debilitating symptoms.
Royal Financial, Inc.
Royal Financial, Inc. Announces Annual Earnings for Fiscal Year 2014
CHICAGO, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Royal Financial, Inc. (the "Company") (OTCBB:RYFL), incorporated under the laws of Delaware on December 15, 2004, for the purpose of serving as the holding company of Royal Savings Bank (the "Bank"), announced earnings for the fiscal year ended June 30, 2014.